London, UK – 14 April 2026 hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that it has signed a Clinical Trial Agreement (“CTA”) to conduct a human challenge (HCT) trial on behalf of Traws Pharma (NASDAQ: TRAW), a clinical-stage biopharmaceutical company developing novel therapies for respiratory viral diseases. The trial will test Traws’ prophylactic antiviral candidate, tivoxavir marboxil (“TXM”), using the hVIVO Influenza Human Challenge…